Cerenome Anticipates $1.55M In Payer Billings In Q3

Cerenome, Inc. (Nasdaq: CNSY) reported that its subsidiary, CNSide Diagnostics, LLC, anticipates $1.55 million in gross payer billings for Q3 2026 from 222 tests billed. The company is also making progress on securing Medicare coverage for its Tumor Cell Enumeration Test (TCE Test) and expanding its testing menu. Initial cash collections from these billings are expected in Q4 2026.